Multimedia
View More
Hear from global experts in this on-demand Webcast capturing a live CCO Webinar focused on leveraging PARP inhibitors and chemotherapy for optimal treatment of pancreatic cancer with BRCA1/2 and other DNA damage repair gene alterations.
Download this slideset to review the latest data on molecular testing considerations for patients with pancreatic cancer.
Download this slideset to review the latest data on treating patients with pancreatic cancer and BRCA mutations or other actionable alterations.
Now that olaparib is approved in the EU, how will your treatment of patients with pancreatic cancer change?
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.